Global Piperacillin Sodium Market
Global Piperacillin Sodium Market

Piperacillin Sodium Comprehensive Study by Type (98% Purity Type, 95% Purity Type), Configuration (Piperacillin Sodium Sulbactam Sodium Injection 8:1, Piperacillin Sodium Sulbactam Sodium Injection 4:1, Piperacillin Sodium Sulbactam Sodium Injection 2:1, Others) Players and Region - Global Market Outlook to 2024

Piperacillin Sodium Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 218 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Piperacillin Sodium Market Overview:
Piperacillin sodium is an organic sodium salt which is used in combination with other antibiotics to treat infections caused by susceptible strains. This drug is in class of penicillin antibiotics, and it works by killing bacteria. Piperacillin shows in-vitro activities against gram-positive and gram-negative bacteria, while it is stable against hydrolysis. Increasing prevalence of organic drugs and rising clinical trails for Piperacillin sodium provide a huge opportunity for manufacturers as well as drug testing agencies.

Market Drivers
  • Growing Use of Piperacillin Sodium in Bacterial Infections
  • Increasing Use of Piperacillin Sodium in Treatment of Extended-Spectrum-Beta-Lactamase-Positive Organisms

Market Trend
  • Growing Adoption of Organic Drugs to Reduce the Side Effects Caused Upon Consumption

Restraints
  • Side Effects, Such as Diarrhea, Constipation and Nausea, Associated with the Use of Piperacillin Sodium

Opportunities
  • Growing Prevalence of Organic Drugs in Various Treatment
  • Advancement in Piperacillin Sodium Research and Development

Challenges
  • Stringent Regulatory Guidelines Pertaining to Drugs Consumption
  • Intricacy Involved in Clinical Trial of the Drugs on Animal


Competitive Landscape:

Some of the key players profiled in the report are LGC Standards (United Kingdom), Clearsynth (Canada), A Chemtek (United States), ALSA Chim (France), Aurora Fine Chemicals (United States) and CSNpharm (United States). Additionally, following companies can also be profiled that are part of our coverage like Biosynth (Switzerland), Muse Chem (United States), 3B Scientific (Germany) and Selleck Chem (United States). Analyst at AdvanceMarketAnalytics see American Vendors to retain maximum share of Global Piperacillin Sodium market by 2024. Considering Market by Configuration, the sub-segment i.e. Piperacillin Sodium Sulbactam Sodium Injection 8:1 will boost the Piperacillin Sodium market.

Market Highlights:

Food and Drug Administration (FDA) regulates the clinical drugs trials and its sales across the United States and others countries. The dosage of this drugs is specified. An individual with serious infections should be given 3 to 4 gram every four to six hours. The maximum daily dose for adult is 24 g/day.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Piperacillin Sodium market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Piperacillin Sodium market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Piperacillin Sodium Manufacturers, Distributors/Suppliers, Drugs Regulatory Bodies, Market and Research Institutes, Government Agencies/Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • 98% Purity Type
  • 95% Purity Type
By Configuration
  • Piperacillin Sodium Sulbactam Sodium Injection 8:1
  • Piperacillin Sodium Sulbactam Sodium Injection 4:1
  • Piperacillin Sodium Sulbactam Sodium Injection 2:1
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Use of Piperacillin Sodium in Bacterial Infections
      • 3.2.2. Increasing Use of Piperacillin Sodium in Treatment of Extended-Spectrum-Beta-Lactamase-Positive Organisms
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Guidelines Pertaining to Drugs Consumption
      • 3.3.2. Intricacy Involved in Clinical Trial of the Drugs on Animal
    • 3.4. Market Trends
      • 3.4.1. Growing Adoption of Organic Drugs to Reduce the Side Effects Caused Upon Consumption
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Piperacillin Sodium, by Type, Configuration and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Piperacillin Sodium (Value)
      • 5.2.1. Global Piperacillin Sodium by: Type (Value)
        • 5.2.1.1. 98% Purity Type
        • 5.2.1.2. 95% Purity Type
      • 5.2.2. Global Piperacillin Sodium by: Configuration (Value)
        • 5.2.2.1. Piperacillin Sodium Sulbactam Sodium Injection 8:1
        • 5.2.2.2. Piperacillin Sodium Sulbactam Sodium Injection 4:1
        • 5.2.2.3. Piperacillin Sodium Sulbactam Sodium Injection 2:1
        • 5.2.2.4. Others
      • 5.2.3. Global Piperacillin Sodium Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Piperacillin Sodium: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. LGC Standards (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Clearsynth (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. A Chemtek (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ALSA Chim (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Aurora Fine Chemicals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CSNpharm (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Piperacillin Sodium Sale, by Type, Configuration and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Piperacillin Sodium (Value)
      • 7.2.1. Global Piperacillin Sodium by: Type (Value)
        • 7.2.1.1. 98% Purity Type
        • 7.2.1.2. 95% Purity Type
      • 7.2.2. Global Piperacillin Sodium by: Configuration (Value)
        • 7.2.2.1. Piperacillin Sodium Sulbactam Sodium Injection 8:1
        • 7.2.2.2. Piperacillin Sodium Sulbactam Sodium Injection 4:1
        • 7.2.2.3. Piperacillin Sodium Sulbactam Sodium Injection 2:1
        • 7.2.2.4. Others
      • 7.2.3. Global Piperacillin Sodium Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Piperacillin Sodium: by Type(USD Million)
  • Table 2. Piperacillin Sodium 98% Purity Type , by Region USD Million (2013-2018)
  • Table 3. Piperacillin Sodium 95% Purity Type , by Region USD Million (2013-2018)
  • Table 4. Piperacillin Sodium: by Configuration(USD Million)
  • Table 5. Piperacillin Sodium Piperacillin Sodium Sulbactam Sodium Injection 8:1 , by Region USD Million (2013-2018)
  • Table 6. Piperacillin Sodium Piperacillin Sodium Sulbactam Sodium Injection 4:1 , by Region USD Million (2013-2018)
  • Table 7. Piperacillin Sodium Piperacillin Sodium Sulbactam Sodium Injection 2:1 , by Region USD Million (2013-2018)
  • Table 8. Piperacillin Sodium Others , by Region USD Million (2013-2018)
  • Table 9. South America Piperacillin Sodium, by Country USD Million (2013-2018)
  • Table 10. South America Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 11. South America Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 12. Brazil Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 13. Brazil Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 14. Argentina Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 15. Argentina Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 16. Rest of South America Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 17. Rest of South America Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 18. Asia Pacific Piperacillin Sodium, by Country USD Million (2013-2018)
  • Table 19. Asia Pacific Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 20. Asia Pacific Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 21. China Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 22. China Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 23. Japan Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 24. Japan Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 25. India Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 26. India Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 27. South Korea Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 28. South Korea Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 29. Taiwan Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 30. Taiwan Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 31. Australia Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 32. Australia Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 33. Rest of Asia-Pacific Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 34. Rest of Asia-Pacific Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 35. Europe Piperacillin Sodium, by Country USD Million (2013-2018)
  • Table 36. Europe Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 37. Europe Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 38. Germany Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 39. Germany Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 40. France Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 41. France Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 42. Italy Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 43. Italy Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 44. United Kingdom Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 45. United Kingdom Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 46. Netherlands Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 47. Netherlands Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 48. Rest of Europe Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 49. Rest of Europe Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 50. MEA Piperacillin Sodium, by Country USD Million (2013-2018)
  • Table 51. MEA Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 52. MEA Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 53. Middle East Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 54. Middle East Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 55. Africa Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 56. Africa Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 57. North America Piperacillin Sodium, by Country USD Million (2013-2018)
  • Table 58. North America Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 59. North America Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 60. United States Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 61. United States Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 62. Canada Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 63. Canada Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 64. Mexico Piperacillin Sodium, by Type USD Million (2013-2018)
  • Table 65. Mexico Piperacillin Sodium, by Configuration USD Million (2013-2018)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Piperacillin Sodium: by Type(USD Million)
  • Table 73. Piperacillin Sodium 98% Purity Type , by Region USD Million (2019-2024)
  • Table 74. Piperacillin Sodium 95% Purity Type , by Region USD Million (2019-2024)
  • Table 75. Piperacillin Sodium: by Configuration(USD Million)
  • Table 76. Piperacillin Sodium Piperacillin Sodium Sulbactam Sodium Injection 8:1 , by Region USD Million (2019-2024)
  • Table 77. Piperacillin Sodium Piperacillin Sodium Sulbactam Sodium Injection 4:1 , by Region USD Million (2019-2024)
  • Table 78. Piperacillin Sodium Piperacillin Sodium Sulbactam Sodium Injection 2:1 , by Region USD Million (2019-2024)
  • Table 79. Piperacillin Sodium Others , by Region USD Million (2019-2024)
  • Table 80. South America Piperacillin Sodium, by Country USD Million (2019-2024)
  • Table 81. South America Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 82. South America Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 83. Brazil Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 84. Brazil Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 85. Argentina Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 86. Argentina Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 87. Rest of South America Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 88. Rest of South America Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 89. Asia Pacific Piperacillin Sodium, by Country USD Million (2019-2024)
  • Table 90. Asia Pacific Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 91. Asia Pacific Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 92. China Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 93. China Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 94. Japan Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 95. Japan Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 96. India Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 97. India Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 98. South Korea Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 99. South Korea Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 100. Taiwan Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 101. Taiwan Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 102. Australia Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 103. Australia Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 104. Rest of Asia-Pacific Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 105. Rest of Asia-Pacific Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 106. Europe Piperacillin Sodium, by Country USD Million (2019-2024)
  • Table 107. Europe Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 108. Europe Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 109. Germany Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 110. Germany Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 111. France Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 112. France Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 113. Italy Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 114. Italy Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 115. United Kingdom Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 116. United Kingdom Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 117. Netherlands Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 118. Netherlands Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 119. Rest of Europe Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 120. Rest of Europe Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 121. MEA Piperacillin Sodium, by Country USD Million (2019-2024)
  • Table 122. MEA Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 123. MEA Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 124. Middle East Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 125. Middle East Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 126. Africa Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 127. Africa Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 128. North America Piperacillin Sodium, by Country USD Million (2019-2024)
  • Table 129. North America Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 130. North America Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 131. United States Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 132. United States Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 133. Canada Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 134. Canada Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 135. Mexico Piperacillin Sodium, by Type USD Million (2019-2024)
  • Table 136. Mexico Piperacillin Sodium, by Configuration USD Million (2019-2024)
  • Table 137. Research Programs/Design for This Report
  • Table 138. Key Data Information from Secondary Sources
  • Table 139. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Piperacillin Sodium: by Type USD Million (2013-2018)
  • Figure 5. Global Piperacillin Sodium: by Configuration USD Million (2013-2018)
  • Figure 6. South America Piperacillin Sodium Share (%), by Country
  • Figure 7. Asia Pacific Piperacillin Sodium Share (%), by Country
  • Figure 8. Europe Piperacillin Sodium Share (%), by Country
  • Figure 9. MEA Piperacillin Sodium Share (%), by Country
  • Figure 10. North America Piperacillin Sodium Share (%), by Country
  • Figure 11. Global Piperacillin Sodium share by Players 2018 (%)
  • Figure 12. Global Piperacillin Sodium share by Players (Top 3) 2018(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. LGC Standards (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 15. LGC Standards (United Kingdom) Revenue: by Geography 2018
  • Figure 16. Clearsynth (Canada) Revenue, Net Income and Gross profit
  • Figure 17. Clearsynth (Canada) Revenue: by Geography 2018
  • Figure 18. A Chemtek (United States) Revenue, Net Income and Gross profit
  • Figure 19. A Chemtek (United States) Revenue: by Geography 2018
  • Figure 20. ALSA Chim (France) Revenue, Net Income and Gross profit
  • Figure 21. ALSA Chim (France) Revenue: by Geography 2018
  • Figure 22. Aurora Fine Chemicals (United States) Revenue, Net Income and Gross profit
  • Figure 23. Aurora Fine Chemicals (United States) Revenue: by Geography 2018
  • Figure 24. CSNpharm (United States) Revenue, Net Income and Gross profit
  • Figure 25. CSNpharm (United States) Revenue: by Geography 2018
  • Figure 26. Global Piperacillin Sodium: by Type USD Million (2019-2024)
  • Figure 27. Global Piperacillin Sodium: by Configuration USD Million (2019-2024)
  • Figure 28. South America Piperacillin Sodium Share (%), by Country
  • Figure 29. Asia Pacific Piperacillin Sodium Share (%), by Country
  • Figure 30. Europe Piperacillin Sodium Share (%), by Country
  • Figure 31. MEA Piperacillin Sodium Share (%), by Country
  • Figure 32. North America Piperacillin Sodium Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • LGC Standards (United Kingdom)
  • Clearsynth (Canada)
  • A Chemtek (United States)
  • ALSA Chim (France)
  • Aurora Fine Chemicals (United States)
  • CSNpharm (United States)
Additional players considered in the study are as follows:
Biosynth (Switzerland) , Muse Chem (United States) , 3B Scientific (Germany) , Selleck Chem (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation